Home >> Industry News >> FDA approves Qiagen CDx for gastrointestinal stromal tumors

FDA approves Qiagen CDx for gastrointestinal stromal tumors

image_pdfCreate PDF

The Therascreen PDGFRA kit uses genomic DNA extracted from a patient’s formalin-fixed, paraffin-embedded tumor tissue. FFPE tumor specimens are processed using the QIAamp DSP DNA FFPE tissue kit for sample preparation and the Rotor-Gene Q MDx instrument for DNA amplification and mutation detection.

CAP TODAY
X